1.	S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068656, S0001, U10CA032102, SWOG-S0001, NCT00017147
2.	O6-Benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000066892, UCCRC-9523, NCI-T98-0038, T98-0038, NCT00003766
3.	O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CWRU1A96, U01CA062502, P30CA043703, NCI-T97-0021, T97-0021, NCT00004072
4.	O6-Benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067671, UCCRC-10227, UCCRC-T99-0088, NCI-T99-0088, NCT00005066
5.	Phase II Study of Carmustine and O6-Benzylguanine in Patients With Recurrent or Progressive Malignant Anaplastic Gliomas (Summary Last Modified 05/2001) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-0059-00-1, DUMC-T98-0059, NCI-T98-0059, NCT00005081, T98-0059
6.	Phase II Study of O6-Benzylguanine and Carmustine in Patients With Unresectable Locally Recurrent or Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10325, CWRU-1699, NCI-T99-0111, NCT00005961, T99-0111
7.	Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU1298, U01CA063200, P30CA043703, NCI-89, 89, NCT00005981
8.	Phase II Study of Carmustine and O6-Benzylguanine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme Not Requiring Immediate Radiotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-3318-01-12, NCI-5632, NCT00046878, 3318-01-12
9.	Phase II Study of Polifeprosan 20 With Carmustine Implant (Gliadel Wafer®) and O6-Benzylguanine in Patients With Recurrent Glioblastoma Multiforme Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: DUMC-5515-06-1R2, DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, NCT00362921
10.	O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000529875, NCI-07-C-0052, AOI-NCI-07-C-0052, NCT00436436
11.	O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors Phase: Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000455561, PBTC-015, NCI-06-C-0089, NCI-P6692, NCT00275002
12.	Phase I Study of O6-Benzylguanine plus Carmustine for Advanced Melanoma, Breast Cancer, Colorectal Cancer, Lymphoma, Gliomas, and Other Adult Solid Tumors (Summary Last Modified 04/2000) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-7341, NCI-T94-0082C, T94-0082
13.	O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CWRU1994, U01CA062502, CWRU-ICC-1994, NCI-T94-0022D, T94-0022, NCT00002604
14.	Phase I Study of Presurgical O6-Benzylguanine in Patients With Malignant Glioma (Summary Last Modified 10/2001) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-9702, NCI-T96-0103, NCT00002971
15.	Phase I Study of Carmustine Plus O6-Benzylguanine in Patients with Recurrent, Persistent, or Progressive Cerebral Anaplastic Gliomas (Summary Last Modified 06/2000) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-1094-99-6R5, DUMC-929-97-6R3, DUMC-980-98-6R4, NCI-T94-0080, NCT00003348, T94-0080
16.	O(6)-Benzylguanine and Carmustine in Treating Patients With Stage I or Stage II Cutaneous T-cell Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CWRU6496, U01CA062502, P30CA043703, CASE-CWRU-6496, NCI-T97-0029, CASE-6496, T97-0029, NCT00003613
17.	Phase I Study of O6-Benzylguanine and Carmustine in Children With Refractory CNS Tumors Phase: Phase I Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: POG-9870, NCT00003765, P9870
18.	Phase I Study of Polifeprosan 20 With Carmustine Implants (Gliadel Wafers) and O6-Benzylguanine in Patients With Recurrent Malignant Glioma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTT-9803, JHOC-NABTT-9803, NCT00004892
19.	Phase I Study of Temozolomide and O6-Benzylguanine in Children With Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI Protocol IDs: NCI-00-C-0105I, NCI-237, 237, NCT00020150
20.	Phase I Study of Temozolomide and O6-Benzylguanine in Patients With Newly Diagnosed or Recurrent or Progressive Cerebral Anaplastic Glioma Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-1388-02-8R2, DUMC-1388-00-8, NCI-490, DUMC-1388-01-8R1, NCT00006474, 490
21.	Phase I Randomized Study of High-Dose Ifosfamide With or Without O6-Benzylguanine in Patients With Unresectable, Metastatic Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-12999B, 6461, NCI-6461, NCT00086970
22.	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Phase: Phase I Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000258738, PBTC-005, NCT00052780
23.	Pilot Study of a Conditioning Regimen Comprising Temozolomide, Radiotherapy, and Busulfan Followed By Genetically Modified Autologous Stem Cell Infusion, Temozolomide, and O6-Benzylguanine in Younger Patients With Newly Diagnosed High-Grade Gliomas Phase: No phase specified Type: Treatment Status: Completed Age: 5 to 55 Sponsor: NCI Protocol IDs: CCHMC-04660, 7036, NCI-7036, NCT00253487
24.	Pilot Study of O6-Benzylguanine and Temozolomide in Combination With Autologous P140K MGMT+ Hematopoietic Progenitors to Protect Hematopoiesis in Patients With Newly Diagnosed Glioblastoma Multiforme Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 to 70 Sponsor: NCI Protocol IDs: CWRU-CASE-6307, CASE-6307, 8274, NCT01269424